51718-80-0

Basic information

• Product Name: METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE
• Synonyms: METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE;Methyl 2-(1H-iMidazol-4-yl)acetate HCl;Methyl 2-(1H-iMidazol-5-yl)acetate hydrochloride;methyl 2-(1H-imidazol-4-yl)acetate
• CAS NO: 51718-80-0
• Molecular Formula: C₆H₈N₂O₂*ClH
• Molecular Weight: 176.6
• Mol File: 51718-80-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE(51718-80-0)
• EPA Substance Registry System: METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE(51718-80-0)

Safety Data

• Hazardous Substances Data: 51718-80-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE is used as a research compound for the development of potential therapeutic agents targeting farnesyl protein transferase. Its ability to inhibit this enzyme makes it a valuable tool in the study and treatment of various diseases associated with the enzyme's dysregulation.
Used in Analytical Chemistry:
METHYL 2-(1H-IMIDAZOL-4-YL)ACETATE HYDROCHLORIDE is used as an analytical reagent in the identification and quantification of farnesyl protein transferase inhibitors. Its specificity for the enzyme allows researchers to better understand the interactions between the compound and the enzyme, which can lead to the development of more effective drugs.

Upstream product

• 645-65-8 2-(1H-imidazol-4-yl)acetic acid 
• 67-56-1 methanol 
• 3251-69-2 imidazole-4-acetic acid hydrochloride 

Downstream Products

• 497159-97-4 methyl {1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl}acetate 
• 145133-11-5 methyl [1-(triphenylmethyl)-1H-imidazol-4-yl]acetate 
• 179025-88-8 1-(4-Nitrophenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester 
• 1610728-66-9 N,N'-(5,5'-((1S,3S)-cyclohexane-1,3-diyl)bis(1,3,4-thiadiazole-5,2-diyl))bis(2-(1H-imidazol-4-yl)acetamide) 
• 872-82-2 2-(1H-imidazol-4-yl)ethanol 
• 497159-99-6 dimethyl 2-({6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}methyl)-2-{1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl}malonate 
• 1027056-58-1 3-(6-amino-pyridin-3-yl)-2-(1-benzyl-1H-imidazol-4-yl)-propionic acid ethyl ester 
• 497159-98-5 dimethyl 2-{1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl}malonate 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS

The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases acc

ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS

Aryl substituted imidazo[4,5-c] pyridine compounds of formula (I) or pharmaceutically acceptable salt thereof are provided. These compounds are useful in pharmaceutical compositions as C3a antagonists for treating a variety of medical conditions associated with the Complement cascade.

INHIBITORS OF HCV NS5B POLYMERASE

The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment and prevention of hepatitis C virus (HCV) infection. In particular, the present invention provides novel compounds, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment or prevention of HCV infection. The present invention also provides processes and intermediates for the synthesis of these compounds.

IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS

The invention relates to compounds of formula (I), which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.

Synthesis and Evaluation of Imidazole Acetic Acid Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor as Novel Antithrombotics

Thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator of fibrinolysis, and inhibitors of this enzyme have potential use in antithrombotic and thrombolytic therapy. Appropriately substituted imidazole acetic acids such as 10j were fo

Inhibitors of prenyl-protein transferase

The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

Inhibitors of prenyl-protein transferase

The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds